- Home
- ANVS vs PSNL Comparison
ANVS vs PSNL Comparison
Compare ANVS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | PSNL |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 872.1M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANVS | PSNL |
|---|---|---|
| Price | $3.66 | $8.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $13.50 | $10.71 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $69,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $2.83 |
| 52 Week High | $5.60 | $11.40 |
Technical Indicators
Market Signals| Indicator | ANVS | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 46.75 |
| Support Level | $3.58 | $7.68 |
| Resistance Level | $4.05 | $9.85 |
| Average True Range (ATR) | 0.39 | 0.59 |
| MACD | -0.16 | -0.23 |
| Stochastic Oscillator | 18.38 | 30.67 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.